Study of Coronary Heart Disease (CHD) & Heart Failure (HF) Risk in Prostate Cancer Patients, Taking Casodex or Not

AstraZeneca

Status: Completed

Conditions: Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT00688532

D6874C00008

Details and patient eligibility

About

A retrospective cohort study performed in the GPRD,UK. All patients with incident prostate cancer identified between 1 Jan 1999 and 31 Dec 2005 and a frequency-matched cohort of the general population will be followed- up for two outcomes; CHD including acute myocardial infarction or death from coronary heart disease and HF until Dec 31, 2006. Outcomes will be validated through requests to primary care physicians. Incidence rate´ratios of CHD and HF in the two cohorts will be calculated. In the cohort of prostate cancer the relative risk of CHD and HF associated with the use of bicalutamide compared to non-use will be estimated.

Enrollment: 5,103 patients

Sex: Male

Ages: 50 to 84 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• At least two years enrollment with the general practitioner

Exclusion criteria

• Patients with cancer before start date of the study

Trial design

5,103 participants in 2 patient groups

1

Description:

Prostate cancer patients treated with bicalutamide or not

2

Description:

General population cohort